WO2010081679A2 - Antibodies against human epo receptor - Google Patents

Antibodies against human epo receptor Download PDF

Info

Publication number
WO2010081679A2
WO2010081679A2 PCT/EP2010/000130 EP2010000130W WO2010081679A2 WO 2010081679 A2 WO2010081679 A2 WO 2010081679A2 EP 2010000130 W EP2010000130 W EP 2010000130W WO 2010081679 A2 WO2010081679 A2 WO 2010081679A2
Authority
WO
WIPO (PCT)
Prior art keywords
seq
region
antibody
heavy chain
variable domain
Prior art date
Application number
PCT/EP2010/000130
Other languages
French (fr)
Other versions
WO2010081679A3 (en
Inventor
Michael Jarsch
Manfred Kubbies
Olaf Mundigl
Nora Torres-Nagel
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Priority to JP2011545672A priority Critical patent/JP2012514985A/en
Priority to US13/144,671 priority patent/US9221909B2/en
Priority to CN201080004518.2A priority patent/CN102282174B/en
Priority to ES10700705.6T priority patent/ES2528219T3/en
Priority to SG2011050168A priority patent/SG172927A1/en
Priority to EP10700705.6A priority patent/EP2387586B1/en
Priority to CA2748758A priority patent/CA2748758C/en
Publication of WO2010081679A2 publication Critical patent/WO2010081679A2/en
Publication of WO2010081679A3 publication Critical patent/WO2010081679A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Definitions

  • EPO Human erythropoietin
  • EPO-R Human EPO receptor
  • EPO-R Human EPO receptor
  • EPO-R is e. g. described in Winkelmann, J.C. et al., Blood 76 (1990) 24- 30 and Jones, S. S. et al., Blood 76 (1990) 31-35. Activation of EPO-R occurs by dimerization (Matthews, D.J., PNAS 93 (1996) 9471-9476). EPO-R comprises eight cytoplasmic tyrosine sites which become phosphorylated upon stimulation with EPO (Li, K. et al., J. Biol. Chem. 278 (2003) 40702-40709; Wu, H.et al., Proc. Natl. Acad. Sci. USA 94 (1997) 1806-1810) resulting in "activated EPO-R".
  • Antibodies against EPO-R are e.g. known from Andrea, A.D., Blood 82 (1993) 46- 52; Elliott, S., Blood 107 (2006) 1892-1895; Kirkeby, A., J. Nerosci. 164 (2007)
  • the invention comprises an antibody specifically binding to activated human EPO receptor and discriminating between non activated and activated EPO-R, which allows specific analysis of the activation of EPO-R especially in cells and biopsies from human tissue.
  • the invention comprises an antibody, characterized in specifically binding human EPO receptor fragment TPPHLKYLYLWSD (SEQ ID NO:25) comprising a phospho-tyrosyl residue at position 430 (underlined), GLSDGPYSNPYENSLIP (SEQ ID NO:26) comprising a phospho-tyrosyl residue at position 461 (underlined), or GLSDGPYSNPYENSLIP (SEQ ID NO:26) comprising a phospho-tyrosyl residue at position 465 (underlined).
  • Numbering relates to EPO receptor amino acid sequence of UniProtKB/Swiss-Prot P 19235 without signal peptide.
  • An antibody according to the invention does not bind EPO receptor fragment TPPHLKYLYLWSD (SEQ ID NO:25) without a phospho-tyrosyl residue at position 430, GLSDGPYSNPYENSLIP (SEQ ID NO:26) without a phospho- tyrosyl residue at position 461, or GLSDGPYSNPYENSLIP (SEQ ID NO:26) without a phospho-tyrosyl residue at position 465.
  • An antibody according to the invention specifically binds phosphorylated (activated) EPO receptor in lysates of UT7 cells which cells are expressing EPO-R in an amount of 100.000 to 500.000 receptors per cell (EPO-R expressing cells) and being treated with 500 pM EPO for activation.
  • An antibody according to the invention does not bind EPO receptor in lysates of UT7 cells expressing EPO receptor and being not treated with EPO. Such binding can be measured by Western Blot.
  • the invention comprises an antibody binding to human EPO-R, characterized in comprising as heavy chain variable domain CDR3 region a CDR3 region of SEQ ID NO: 1, 9 or 17.
  • the antibody is characterized in that the heavy chain variable domain comprises CDR3 region of SEQ ID NO: 1 , a CDR2 region of SEQ ID NO:2 and a
  • the antibody is characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO:2 and a CDRl region of SEQ ID NO: 3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5 and a CDRl region of SEQ ID NO:6.
  • the antibody is characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 9, a CDR2 region of SEQ ID NO: 10 and a CDRl region of SEQ ID NO: 11 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO: 12, a CDR2 region of SEQ ID NO: 13 and a CDRl region of SEQ ID NO: 14.
  • the antibody is characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 17, a CDR2 region of SEQ ID NO: 18 and a CDRl region of SEQ ID NO: 19 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO: 20, a CDR2 region of SEQ ID NO:21 and a CDRl region of SEQ ID NO:22.
  • the antibody is characterized in that the heavy chain variable domain comprises SEQ ID NO:7, 15 or 23.
  • the antibody is characterized in that the light chain variable domain comprises SEQ ID NO:8, 16 or 24.
  • the antibody is characterized in that the heavy chain variable domain comprises SEQ ID NO:7 and the light chain variable domain comprises SEQ ID NO:8.
  • the antibody is characterized in that the heavy chain variable domain comprises SEQ ID NO: 15 and the light chain variable domain comprises SEQ ID NO: 16.
  • the antibody is characterized in that the heavy chain variable domain comprises SEQ ID NO:23 and the light chain variable domain comprises SEQ ID NO:24.
  • the antibody according to the invention is characterized in binding to EPO-R with a binding affinity of at least 10 "8 M “1 to 10 12 M “1 .
  • a further embodiment of the invention is a nucleic acid encoding a heavy chain and a light chain of an antibody according to the invention.
  • Human and other constant chains are well known in the state of the art and e.g. described by Kabat (see e.g. Johnson, G. and Wu, T.T., Nucleic Acids Res. 28 (2000) 214-218).
  • the antibody is of mouse origin and comprises the antibody variable sequence frame of a mouse antibody according to Kabat (see e.g. Johnson, G. and Wu, T.T., Nucleic Acids Res. 28 (2000) 214-218).
  • the antibody according to the invention is preferably of mouse, rabbit or human origin.
  • human antibody isotype IgGl is preferred.
  • the invention further provides expression vectors containing nucleic acid according to the invention capable of expressing said nucleic acid in a prokaryotic or eukaryotic host cell, and host cells containing such vectors for the recombinant production of such an antibody.
  • the invention further comprises a prokaryotic or eukaryotic host cell comprising a vector according to the invention.
  • the invention further comprises a method for the production of a recombinant human or humanized antibody according to the invention, characterized by expressing a nucleic acid according to the invention in a prokaryotic or eukaryotic host cell and recovering said antibody from said cell or the cell culture supernatant.
  • the invention further comprises the antibody obtainable by such a recombinant method.
  • the invention further comprises the use of an antibody according to the invention to determine/detect mammalian cells bearing/expressing activated EPO receptor.
  • an antibody according to the invention is used to determine activated EPO receptor in lysates of biopsies of human tissue samples.
  • detection is performed by Western Blot.
  • antibody encompasses the various forms of antibody structures including but not being limited to whole antibodies and antibody fragments.
  • Antibody fragments comprise a portion of a full length antibody, preferably the variable domain thereof, or at least the antigen binding site thereof.
  • Examples of antibody fragments include diabodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments.
  • scFv antibodies are, e.g., described in Houston, J.S., Methods Enzymol. 203 (1991) 46-88.
  • antibody fragments comprise single chain polypeptides having the characteristics of a V H domain, namely being able to assemble together with a V L domain, or of a V L domain binding to EPO-R, namely being able to assemble together with a V H domain to a functional antigen binding site and thereby providing an antibody with the properties of specifically binding to human EPO-R.
  • humanized antibody refers to antibodies in which the framework and/or "complementarity determining regions” (CDR) have been modified to comprise the CDR of an immunoglobulin of different species as compared to that of the parent immunoglobulin.
  • CDR complementarity determining regions
  • a mouse CDR is grafted into the framework region of a human antibody to prepare the "humanized antibody”. See, e.g., Riechmann, L. et al., Nature 332 (1988) 323-327; and Neuberger, M.S. et al., Nature 314 (1985) 268-270.
  • the term "comprises a heavy chain CDR3 region of SEQ ID NO:1" denotes that the antibody comprises as sequence of its heavy chain CDR3 region the amino acid sequence of SEQ ID NO: 1. The same denotes for the other five CDR regions of the antibody.
  • binding to activated EPO-R means binding of the antibody to human activated EPO-R in a biochemical binding assay measured by Western Blotting. Binding is found if the antibody causes an S/N (signal/noise) ratio of 400 or more at an antibody concentration of l ⁇ g/ml.
  • the term "not binding to EPO-R” as used herein means binding of the antibody to human EPO-R in a biochemical binding assay measured by Western Blotting. No binding is found if the antibody causes an S/N (signal/noise) ratio of lower than 400 at an antibody concentration of 1 ⁇ g/ml. Binding of the antibodies according to the invention to non activated EPO R is not detectable in Western Blots, therefore the S/N ratio is even lower than 10 and preferably about 1 or lower.
  • binding of EPO to EPO receptor means binding of the EPO to human activated EPO-R in a biochemical binding assay measured by Western Blotting. No binding is found if EPO causes an S/N (signal/noise) ratio of no more than 10 at an EPO concentration of l ⁇ g/ml.
  • pY430 as used herein means a 17 amino-acid synthetic peptide corresponding to residues 424-437 of the mature human erythropoietin receptor (TPPHLKYLYLWSD, SEQ ID NO:25), comprising a phospho-tyrosyl residue at position 43O.
  • pY461 as used herein means a 17 amino-acid synthetic peptide corresponding to residues 455-471 of the mature human erythropoietin receptor (GLSDGPYSNPYENSLIP, SEQ ID NO:26), comprising a phospho- tyrosyl residue at position 461.
  • pY465" as used herein means a 17 amino-acid synthetic peptide corresponding to residues 455-471 of the mature human erythropoietin receptor (GLSDGPYSNPYENSLIP, SEQ ID NO:26), comprising a phospho-tyrosyl residue at position 465.
  • the antibody according to the invention is characterized in specifically binding pY430, pY461 or pY465 in ELISA at a S/N ratio of 10 or more at an antibody concentration of 0.1 ⁇ g/ml .
  • variable domain denotes each of the pair of light and heavy chain domains which are involved directly in binding the antibody to the antigen.
  • the variable light and heavy chain domains have the same general structure and each domain comprises four framework (FR) regions whose sequences are widely conserved, connected by three "hypervariable regions” (or complementarity determining regions, CDRs).
  • the framework regions adopt a ⁇ -sheet conformation and the CDRs may form loops connecting the ⁇ -sheet structure.
  • the CDRs in each chain are held in their three-dimensional structure by the framework regions and form together with the CDRs from the other chain the antigen binding site.
  • the antibody's heavy and light chain CDR3 regions play a particularly important role in the binding specificity/affinity of the antibodies according to the invention and therefore provide a further object of the invention.
  • antigen-binding portion of an antibody when used herein refer to the amino acid residues of an antibody which are responsible for antigen-binding.
  • the antigen-binding portion of an antibody comprises amino acid residues from the "complementarity determining regions" or "CDRs".
  • CDRs complementarity determining regions
  • FR Framework regions are those variable domain regions other than the hypervariable region residues as herein defined. Therefore, the light and heavy chain variable domains of an antibody comprise from N- to C-terminus the domains FRl, CDRl, FR2, CDR2,
  • CDR3 of the heavy chain is the region which contributes most to antigen binding and defines the antibody's properties.
  • CDR and FR regions are determined according to the standard definition of Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) and/or those residues from a "hypervariable loop".
  • nucleic acid or “nucleic acid molecule”, as used herein, are intended to include DNA molecules and RNA molecules.
  • a nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.
  • amino acid denotes the group of naturally occurring carboxy ⁇ -amino acids comprising alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gin, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine
  • phenylalanine phe, F
  • proline pro, P
  • serine serine
  • threonine thr, T
  • tryptophan trp, W
  • tyrosine tyr, Y
  • valine val, V
  • a nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid.
  • DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide;
  • a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or
  • a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation.
  • "operably linked” means that the DNA sequences being linked are colinear, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
  • the expressions "cell”, “cell line”, and “cell culture” are used interchangeably and all such designations include progeny.
  • the words “transformants” and “transformed cells” include the primary subject cell and cultures derived there from without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Variant progeny that have the same function or biological activity as screened for in the originally transformed cell are included.
  • useful human heavy chain constant region comprises an amino acid of SEQ ID NO: 23.
  • an useful human light chain constant region comprises an amino acid sequence of a kappa-light chain constant region of SEQ ID NO: 24.
  • the invention comprises a method for detecting or determination of activated EPO- R in human cells tissues, and biopsies.
  • the invention comprises the use of an antibody according to the invention for diagnosis of activated EPO-R in human cells tissues, and biopsies.
  • the invention comprises the use of an antibody according to the invention for the preparation of a diagnostis assay for detecting or determining activated EPO-R in human cells tissues, and biopsies.
  • the antibodies according to the invention include, in addition, such antibodies having "conservative sequence modifications" (variant antibodies), nucleotide and amino acid sequence modifications which do not affect or alter the above- mentioned characteristics of the antibody according to the invention. Modifications can be introduced by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions include ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art.
  • amino acids with basic side chains e.g. lysine, arginine, histidine
  • acidic side chains e.g. aspartic acid, glutamic acid
  • uncharged polar side chains e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan
  • nonpolar side chains e.g. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine
  • beta-branched side chains e.g. threonine, valine, isoleucine
  • aromatic side chains e.g.
  • a “variant" anti-EPO-R antibody refers therefore herein to a molecule which differs in amino acid sequence from a "parent" anti- EPO-R antibody amino acid sequence by up to ten, preferably from about two to about five, additions, deletions and/or substitutions in one or more variable region of the parent antibody.
  • Amino acid substitutions can be performed by mutagenesis based upon molecular modeling as described by Riechmann, L. et al., Nature 332 (1988) 323-327 and Queen, C. et al., Proc. Natl. Acad. Sci. USA 86 (1989) 10029-10033.
  • the antibodies according to the invention are preferably produced by recombinant means. Such methods are widely known in the state of the art and comprise protein expression in prokaryotic and eukaryotic cells with subsequent isolation of the antibody polypeptide and usually purification to a pharmaceutically acceptable purity.
  • nucleic acids encoding light and heavy chains or fragments thereof are inserted into expression vectors by standard methods.
  • Expression is performed in appropriate prokaryotic or eukaryotic host cells, such as CHO cells, NSO cells, SP2/0 cells, HEK293 cells, COS cells, yeast, or E. coli cells, and the antibody is recovered from the cells (from the supernatant or after cells lysis).
  • prokaryotic or eukaryotic host cells such as CHO cells, NSO cells, SP2/0 cells, HEK293 cells, COS cells, yeast, or E. coli cells
  • the antibodies may be present in whole cells, in a cell lysate, or in a partially purified, or substantially pure form. Purification is performed in order to eliminate other cellular components or other contaminants, e.g. other cellular nucleic acids or proteins, by standard techniques, including alkaline/SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis, and others well known in the art. See Ausubel, F., et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).
  • variable domains Cloning of variable domains is described by Orlandi, R., et al., Proc.
  • HEK 293 A preferred transient expression system (HEK 293) is described by Schlaeger, E.-J. and Christensen, K., in Cytotechnology 30 (1999) 71-83, and by
  • Monoclonal antibodies are suitably separated from the culture medium by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography.
  • DNA and RNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures.
  • the hybridoma cells can serve as a source of such DNA and RNA.
  • the DNA may be inserted into expression vectors, which are then transfected into host cells, such as HEK 293 cells, CHO cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of recombinant monoclonal antibodies in the host cells.
  • Amino acid sequence variants of human EPO-R antibody are prepared by introducing appropriate nucleotide changes into the antibody encoding DNA, or by peptide synthesis. Such modifications can be performed, however, only in a very limited range, e.g. as described above. For example, the modifications do not alter the abovementioned antibody characteristics such as the IgG isotype and epitope binding, but may improve the yield of the recombinant production, protein stability, or facilitate the purification.
  • cysteine residues not involved in maintaining the proper conformation of the anti- EPO-R antibody may also be substituted, generally with serine, to improve the oxidative stability of the molecule and to prevent aberrant crosslinking.
  • cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).
  • Nucleic acid molecules encoding amino acid sequence variants of anti- EPO-R antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of humanized anti- EPO-R antibody.
  • the heavy and light chain variable domains according to the invention are combined with sequences of promoter, translation initiation, constant region, 3' untranslated region, polyadenylation, and transcription termination to form expression vector constructs.
  • the heavy and light chain expression constructs can be combined into a single vector, co-transfected, serially transfected, or separately transfected into host cells which are then fused to form a single host cell expressing both chains.
  • the present invention provides a diagnostic composition, e.g. for the determination of activated EPO-R in human cells tissues, and biopsies.
  • Figure 1 Time dependent phosphorylation of human EPOR in UT-
  • pY430 (Cl.16.7.5): a 17 amino-acid synthetic peptide corresponding to residues
  • TPPHLKYLYLVVSD mature human erythropoietin receptor
  • SEQ ID NO:25 mature human erythropoietin receptor
  • pY461 Cl.8.7.16: a 17 amino-acid synthetic peptide corresponding to residues 455-471 of the mature human erythropoietin receptor (GLSDGPYSNP YENSLIP,
  • SEQ ID NO:26 comprising a phospho-tyrosyl residue at position 461 was used as immunogen.
  • pY465 (Cl.24.11.31): a 17 amino-acid synthetic peptide corresponding to residues 455-471 of the mature human erythropoietin receptor (GLSDGP YSNPYENSLIP, SEQ ID NO:26), comprising a phospho-tyrosyl residue at position 465 was used as immunogen.
  • mice were immunized with immunogen every four weeks for 3 times followed by an i.v. boost on day 4 before fusion, splenocytes were harvested, and fused with Ag8 myeloma cells. Screening for phospho-specific antibodies was done by differential testing on phospho -vs. non-phospho form of the peptide (which otherwise was identical to the phospho-peptide) using peptide coated ELISA microtiter plates following standard procedues. Antibody clones were selected because they detected one specific band corresponding to the EPOR on Western Blots of cell lysates that have been stimulated with EPO (example 2).
  • the SDS-PAGE and Western blotting were performed according to standard procedures and the Nupage® gel system of Invitrogen.
  • the lysates corresponding to 5.10 4 -10 5 cells were loaded in each line of a Nupage® Novex 4-12% Bis-Tris gel.
  • the proteins were then transferred onto PVDF (Polyvinylidene Fluoride) membranes and incubated with the antibodies and anti-GAPDH antibody (Abeam m9484, Abeam pic UK)) for 2 hours at room temperature or overnight at 4°C . After washing, the membranes were incubated with a conjugate anti-mouse IgG- POD and developed using ECL reagents (Lumi-LightPLUS Western blotting substrate, Roche Applied Science #2015218).
  • Antibodies C1.24.11.31, Cl.16.7.5 and Cl.8.7.16 were selected as binding specifically to activated EPO receptor only without binding to non-activated EPO receptor (Fig.l).
  • UT-7 cell line is a human factor-dependent erythroleukemic cell line (Human bone marrow acute myeloid leukemia cell line DSMZ: ACC 137), requiring EPO for long-term growth.
  • UT7 cells were maintained in RPMI medium comprising in addition L-glutamine (2mM), non-essential amino acids (Ix), and sodium pyruvate
  • Transduced cells (UT7/EPOR) were maintained in the same medium as untransduced (25U/ml GM-CSF instead of 10U/ml) with the addition of 0.4 mg/ml zeocine. Before each stimulation the cells were starved by incubation overnight in RPMI media supplemented with L-glutamine (2mM), non-essential amino acids
  • UT-7 cells were transduced with the supernatant from GP2-293 (Clontech Laboratories, Inc) cells transiently transfected with a retroviral expression vector encoding hEPOR and pVSV-G (an expression vector encoding the G glycoprotein of the rhabdovirus vesicular stomatitis virus). Two days after transduction the medium was replaced with fresh supplemented RPMI containing 0.4 mg/ml zeocine and 25U/ml GM-CSF. After selection a cell line of UT-7 cells stable expressing EPOR on their surface was obtained. Stimulation:
  • Serum starved cells were stimulated for the times indicated with 500 pM erythropoietin in starvation medium (supplemented with 0.1% fetal calf serum) at 37°C for 1, 3 and 5 minutes. After stimulation the cells were centrifuged, the medium was discarded and the pellet was incubated in ice-cold lysis buffer [Tris 20 mM (pH7.4), NaCl 137 mM, Glycerol 10%, Nonidet® P-40 1% , protease inhibitors Ix (Pierce, # 78410), phosphatase inhibitors Ix (Pierce #78420)] for 30 minutes at 4°C followed by centrifugation at 13000 rpm for 10 minutes at 4°C. The lysate supernatant was boiled in sample buffer (Nupage®, Invitrogen) in the presence of a reducing agent and either directly used for SDS-PAGE.
  • sample buffer Nupage®, Invitrogen
  • UT7/EPOR cells were stimulated as described above and analyzed by Western Blot.
  • the Mabs recognize one band at MW 66kD corresponding to the EPOR (Fig.l) in cells that are stimulated with 0.5nM EPO for 1-5 min.
  • Fig.l As loading control GAPDH was used.
  • ESAs erythropoietin stimulating agents

Abstract

An antibody binding to human EPO-R, characterized in specifically binding pY461, pY430 or p465 is useful for the determination of activated EPO receptor.

Description

Antibodies against human EPO Receptor Background of the Invention
Human erythropoietin (EPO) is a 166-aa glycoprotein which is involved in the proliferation and differentiation of erythroid progenitor cells. These cellular responses are mediated by the human EPO receptor (EPO-R), a 508-aa glycoprotein. Human EPO receptor (EPO-R) is a protein of 508 amino acid length
(Swiss Prot P 19235) containing a single transmembrane domain and has been classified as a member of the growth hormone subfamily of class I cytokine receptors. EPO-R is e. g. described in Winkelmann, J.C. et al., Blood 76 (1990) 24- 30 and Jones, S. S. et al., Blood 76 (1990) 31-35. Activation of EPO-R occurs by dimerization (Matthews, D.J., PNAS 93 (1996) 9471-9476). EPO-R comprises eight cytoplasmic tyrosine sites which become phosphorylated upon stimulation with EPO (Li, K. et al., J. Biol. Chem. 278 (2003) 40702-40709; Wu, H.et al., Proc. Natl. Acad. Sci. USA 94 (1997) 1806-1810) resulting in "activated EPO-R".
Antibodies against EPO-R are e.g. known from Andrea, A.D., Blood 82 (1993) 46- 52; Elliott, S., Blood 107 (2006) 1892-1895; Kirkeby, A., J. Nerosci. 164 (2007)
50-58; Miura, O., Arch. Biochem. 306 (1993) 200-208; and EP 1 146 056, EP 1
327 681, EP 0 773 962, EP 0 776 370, US 2002/0031806, US 2003/0215444,
US 2004/0058393, US 2004/0071694, US 2004/0175379, US 2005/0227289,
US 2005/0244409, US 2006/0018902, US 6,998,124, US 7,053,184, US 7,081,523, WO 1995/005469, WO 1996/003438, WO 2000/061637, WO 2004/035603 A2,
WO 2005/100403 A2. However it is known form the state of the art, that known antibodies against EPO-R are not able to discriminate between non activated and activated EPO-R (see Jelkmann, W. et al., Crit. Rev. Onc/Hematol. 67 (2008) 39-
61; Li, K. et al., J. Biol. Chem. 278 (2003) 40702-40709, and Wu, H. et al., Proc. Natl. Acad. Sci. USA 94 (1997) 1806-1810).
Summary of the Invention
The invention comprises an antibody specifically binding to activated human EPO receptor and discriminating between non activated and activated EPO-R, which allows specific analysis of the activation of EPO-R especially in cells and biopsies from human tissue. The invention comprises an antibody, characterized in specifically binding human EPO receptor fragment TPPHLKYLYLWSD (SEQ ID NO:25) comprising a phospho-tyrosyl residue at position 430 (underlined), GLSDGPYSNPYENSLIP (SEQ ID NO:26) comprising a phospho-tyrosyl residue at position 461 (underlined), or GLSDGPYSNPYENSLIP (SEQ ID NO:26) comprising a phospho-tyrosyl residue at position 465 (underlined).
Numbering relates to EPO receptor amino acid sequence of UniProtKB/Swiss-Prot P 19235 without signal peptide.
An antibody according to the invention does not bind EPO receptor fragment TPPHLKYLYLWSD (SEQ ID NO:25) without a phospho-tyrosyl residue at position 430, GLSDGPYSNPYENSLIP (SEQ ID NO:26) without a phospho- tyrosyl residue at position 461, or GLSDGPYSNPYENSLIP (SEQ ID NO:26) without a phospho-tyrosyl residue at position 465.
An antibody according to the invention specifically binds phosphorylated (activated) EPO receptor in lysates of UT7 cells which cells are expressing EPO-R in an amount of 100.000 to 500.000 receptors per cell (EPO-R expressing cells) and being treated with 500 pM EPO for activation. An antibody according to the invention does not bind EPO receptor in lysates of UT7 cells expressing EPO receptor and being not treated with EPO. Such binding can be measured by Western Blot.
Preferably the invention comprises an antibody binding to human EPO-R, characterized in comprising as heavy chain variable domain CDR3 region a CDR3 region of SEQ ID NO: 1, 9 or 17.
Preferably the antibody is characterized in that the heavy chain variable domain comprises CDR3 region of SEQ ID NO: 1 , a CDR2 region of SEQ ID NO:2 and a
CDRl region of SEQ ID NO:3 or CDR3 region of SEQ ID NO:9, a CDR2 region of SEQ ID NO: 10 and a CDRl region of SEQ ID NO:11 or CDR3 region of SEQ ID NO: 17, a CDR2 region of SEQ ID NO: 18 and a CDRl region of SEQ ID NO:19.
Preferably the antibody is characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO:2 and a CDRl region of SEQ ID NO: 3 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5 and a CDRl region of SEQ ID NO:6.
Preferably the antibody is characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 9, a CDR2 region of SEQ ID NO: 10 and a CDRl region of SEQ ID NO: 11 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO: 12, a CDR2 region of SEQ ID NO: 13 and a CDRl region of SEQ ID NO: 14.
Preferably the antibody is characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 17, a CDR2 region of SEQ ID NO: 18 and a CDRl region of SEQ ID NO: 19 and in that the light chain variable domain comprises a CDR3 region of SEQ ID NO: 20, a CDR2 region of SEQ ID NO:21 and a CDRl region of SEQ ID NO:22.
Preferably the antibody is characterized in that the heavy chain variable domain comprises SEQ ID NO:7, 15 or 23. Preferably the antibody is characterized in that the light chain variable domain comprises SEQ ID NO:8, 16 or 24.
Preferably the antibody is characterized in that the heavy chain variable domain comprises SEQ ID NO:7 and the light chain variable domain comprises SEQ ID NO:8. Preferably the antibody is characterized in that the heavy chain variable domain comprises SEQ ID NO: 15 and the light chain variable domain comprises SEQ ID NO: 16.
Preferably the antibody is characterized in that the heavy chain variable domain comprises SEQ ID NO:23 and the light chain variable domain comprises SEQ ID NO:24.
Preferably the antibody according to the invention is characterized in binding to EPO-R with a binding affinity of at least 10"8 M"1 to 10 12 M"1 .
A further embodiment of the invention is a nucleic acid encoding a heavy chain and a light chain of an antibody according to the invention. Human and other constant chains are well known in the state of the art and e.g. described by Kabat (see e.g. Johnson, G. and Wu, T.T., Nucleic Acids Res. 28 (2000) 214-218). It is further preferred that the antibody is of mouse origin and comprises the antibody variable sequence frame of a mouse antibody according to Kabat (see e.g. Johnson, G. and Wu, T.T., Nucleic Acids Res. 28 (2000) 214-218).
The antibody according to the invention is preferably of mouse, rabbit or human origin. As human antibody isotype IgGl is preferred.
The invention further provides expression vectors containing nucleic acid according to the invention capable of expressing said nucleic acid in a prokaryotic or eukaryotic host cell, and host cells containing such vectors for the recombinant production of such an antibody.
The invention further comprises a prokaryotic or eukaryotic host cell comprising a vector according to the invention.
The invention further comprises a method for the production of a recombinant human or humanized antibody according to the invention, characterized by expressing a nucleic acid according to the invention in a prokaryotic or eukaryotic host cell and recovering said antibody from said cell or the cell culture supernatant. The invention further comprises the antibody obtainable by such a recombinant method.
The invention further comprises the use of an antibody according to the invention to determine/detect mammalian cells bearing/expressing activated EPO receptor.
Preferably an antibody according to the invention is used to determine activated EPO receptor in lysates of biopsies of human tissue samples. Preferably such detection is performed by Western Blot.
Detailed Description of the Invention
The term "antibody" encompasses the various forms of antibody structures including but not being limited to whole antibodies and antibody fragments.
"Antibody fragments" comprise a portion of a full length antibody, preferably the variable domain thereof, or at least the antigen binding site thereof. Examples of antibody fragments include diabodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments. scFv antibodies are, e.g., described in Houston, J.S., Methods Enzymol. 203 (1991) 46-88. In addition, antibody fragments comprise single chain polypeptides having the characteristics of a VH domain, namely being able to assemble together with a VL domain, or of a VL domain binding to EPO-R, namely being able to assemble together with a VH domain to a functional antigen binding site and thereby providing an antibody with the properties of specifically binding to human EPO-R.
The term "humanized antibody" refers to antibodies in which the framework and/or "complementarity determining regions" (CDR) have been modified to comprise the CDR of an immunoglobulin of different species as compared to that of the parent immunoglobulin. In a preferred embodiment, a mouse CDR is grafted into the framework region of a human antibody to prepare the "humanized antibody". See, e.g., Riechmann, L. et al., Nature 332 (1988) 323-327; and Neuberger, M.S. et al., Nature 314 (1985) 268-270.
The term "comprises a heavy chain CDR3 region of SEQ ID NO:1" denotes that the antibody comprises as sequence of its heavy chain CDR3 region the amino acid sequence of SEQ ID NO: 1. The same denotes for the other five CDR regions of the antibody.
The term "binding to activated EPO-R" as used herein means binding of the antibody to human activated EPO-R in a biochemical binding assay measured by Western Blotting. Binding is found if the antibody causes an S/N (signal/noise) ratio of 400 or more at an antibody concentration of lμg/ml. The term "not binding to EPO-R" as used herein means binding of the antibody to human EPO-R in a biochemical binding assay measured by Western Blotting. No binding is found if the antibody causes an S/N (signal/noise) ratio of lower than 400 at an antibody concentration of 1 μg/ml. Binding of the antibodies according to the invention to non activated EPO R is not detectable in Western Blots, therefore the S/N ratio is even lower than 10 and preferably about 1 or lower.
The term "binding of EPO to EPO receptor" as used herein means binding of the EPO to human activated EPO-R in a biochemical binding assay measured by Western Blotting. No binding is found if EPO causes an S/N (signal/noise) ratio of no more than 10 at an EPO concentration of lμg/ml.
The term "pY430" as used herein means a 17 amino-acid synthetic peptide corresponding to residues 424-437 of the mature human erythropoietin receptor (TPPHLKYLYLWSD, SEQ ID NO:25), comprising a phospho-tyrosyl residue at position 43O.The term "pY461" as used herein means a 17 amino-acid synthetic peptide corresponding to residues 455-471 of the mature human erythropoietin receptor (GLSDGPYSNPYENSLIP, SEQ ID NO:26), comprising a phospho- tyrosyl residue at position 461. The term "pY465" as used herein means a 17 amino-acid synthetic peptide corresponding to residues 455-471 of the mature human erythropoietin receptor (GLSDGPYSNPYENSLIP, SEQ ID NO:26), comprising a phospho-tyrosyl residue at position 465.
The antibody according to the invention is characterized in specifically binding pY430, pY461 or pY465 in ELISA at a S/N ratio of 10 or more at an antibody concentration of 0.1 μg/ml .
The "variable domain" (variable domain of a light chain (VL), variable domain of a heavy chain (VH)) as used herein denotes each of the pair of light and heavy chain domains which are involved directly in binding the antibody to the antigen. The variable light and heavy chain domains have the same general structure and each domain comprises four framework (FR) regions whose sequences are widely conserved, connected by three "hypervariable regions" (or complementarity determining regions, CDRs). The framework regions adopt a β-sheet conformation and the CDRs may form loops connecting the β-sheet structure. The CDRs in each chain are held in their three-dimensional structure by the framework regions and form together with the CDRs from the other chain the antigen binding site. The antibody's heavy and light chain CDR3 regions play a particularly important role in the binding specificity/affinity of the antibodies according to the invention and therefore provide a further object of the invention.
The term "antigen-binding portion of an antibody" when used herein refer to the amino acid residues of an antibody which are responsible for antigen-binding. The antigen-binding portion of an antibody comprises amino acid residues from the "complementarity determining regions" or "CDRs". "Framework" or "FR" regions are those variable domain regions other than the hypervariable region residues as herein defined. Therefore, the light and heavy chain variable domains of an antibody comprise from N- to C-terminus the domains FRl, CDRl, FR2, CDR2,
FR3, CDR3, and FR4. Especially, CDR3 of the heavy chain is the region which contributes most to antigen binding and defines the antibody's properties. CDR and FR regions are determined according to the standard definition of Kabat et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) and/or those residues from a "hypervariable loop".
The terms "nucleic acid" or "nucleic acid molecule", as used herein, are intended to include DNA molecules and RNA molecules. A nucleic acid molecule may be single-stranded or double-stranded, but preferably is double-stranded DNA.
The term "amino acid" as used within this application denotes the group of naturally occurring carboxy α-amino acids comprising alanine (three letter code: ala, one letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine (cys, C), glutamine (gin, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine
(met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).
A nucleic acid is "operably linked" when it is placed into a functional relationship with another nucleic acid. For example, DNA for a presequence or secretory leader is operably linked to DNA for a polypeptide if it is expressed as a preprotein that participates in the secretion of the polypeptide; a promoter or enhancer is operably linked to a coding sequence if it affects the transcription of the sequence; or a ribosome binding site is operably linked to a coding sequence if it is positioned so as to facilitate translation. Generally, "operably linked" means that the DNA sequences being linked are colinear, and, in the case of a secretory leader, contiguous and in reading frame. However, enhancers do not have to be contiguous. Linking is accomplished by ligation at convenient restriction sites. If such sites do not exist, synthetic oligonucleotide adaptors or linkers are used in accordance with conventional practice.
As used herein, the expressions "cell", "cell line", and "cell culture" are used interchangeably and all such designations include progeny. Thus, the words "transformants" and "transformed cells" include the primary subject cell and cultures derived there from without regard for the number of transfers. It is also understood that all progeny may not be precisely identical in DNA content, due to deliberate or inadvertent mutations. Variant progeny that have the same function or biological activity as screened for in the originally transformed cell are included.
Examples of useful human heavy chain constant region comprises an amino acid of SEQ ID NO: 23. For example an useful human light chain constant region comprises an amino acid sequence of a kappa-light chain constant region of SEQ ID NO: 24.
The invention comprises a method for detecting or determination of activated EPO- R in human cells tissues, and biopsies.
The invention comprises the use of an antibody according to the invention for diagnosis of activated EPO-R in human cells tissues, and biopsies.
The invention comprises the use of an antibody according to the invention for the preparation of a diagnostis assay for detecting or determining activated EPO-R in human cells tissues, and biopsies. The antibodies according to the invention include, in addition, such antibodies having "conservative sequence modifications" (variant antibodies), nucleotide and amino acid sequence modifications which do not affect or alter the above- mentioned characteristics of the antibody according to the invention. Modifications can be introduced by standard techniques known in the art, such as site-directed mutagenesis and PCR-mediated mutagenesis. Conservative amino acid substitutions include ones in which the amino acid residue is replaced with an amino acid residue having a similar side chain. Families of amino acid residues having similar side chains have been defined in the art. These families include amino acids with basic side chains (e.g. lysine, arginine, histidine), acidic side chains (e.g. aspartic acid, glutamic acid), uncharged polar side chains (e.g. glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine, tryptophan), nonpolar side chains (e.g. alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g. threonine, valine, isoleucine) and aromatic side chains (e.g. tyrosine, phenylalanine, tryptophan, histidine). Thus, a predicted nonessential amino acid residue in a human anti- EPO-R antibody can be preferably replaced with another amino acid residue from the same side chain family. A "variant" anti-EPO-R antibody, refers therefore herein to a molecule which differs in amino acid sequence from a "parent" anti- EPO-R antibody amino acid sequence by up to ten, preferably from about two to about five, additions, deletions and/or substitutions in one or more variable region of the parent antibody.
Amino acid substitutions can be performed by mutagenesis based upon molecular modeling as described by Riechmann, L. et al., Nature 332 (1988) 323-327 and Queen, C. et al., Proc. Natl. Acad. Sci. USA 86 (1989) 10029-10033. The antibodies according to the invention are preferably produced by recombinant means. Such methods are widely known in the state of the art and comprise protein expression in prokaryotic and eukaryotic cells with subsequent isolation of the antibody polypeptide and usually purification to a pharmaceutically acceptable purity. For the protein expression nucleic acids encoding light and heavy chains or fragments thereof are inserted into expression vectors by standard methods. Expression is performed in appropriate prokaryotic or eukaryotic host cells, such as CHO cells, NSO cells, SP2/0 cells, HEK293 cells, COS cells, yeast, or E. coli cells, and the antibody is recovered from the cells (from the supernatant or after cells lysis).
Recombinant production of antibodies is well-known in the state of the art and described, for example, in the review articles of Makrides, S. C, Protein Expr. Purif. 17 (1999) 183-202; Geisse, S. et al., Protein Expr. Purif. 8 (1996) 271-282; Kaufman, R.J., MoI. Biotechnol. 16 (2000) 151-161; Werner, R.G., Drug Res. 48 (1998) 870-880.
The antibodies may be present in whole cells, in a cell lysate, or in a partially purified, or substantially pure form. Purification is performed in order to eliminate other cellular components or other contaminants, e.g. other cellular nucleic acids or proteins, by standard techniques, including alkaline/SDS treatment, CsCl banding, column chromatography, agarose gel electrophoresis, and others well known in the art. See Ausubel, F., et al., ed. Current Protocols in Molecular Biology, Greene Publishing and Wiley Interscience, New York (1987).
Expression in NSO cells is described by, e.g., Barnes, L.M., et al., Cytotechnology
32 (2000) 109-123; Barnes, L.M., et al., Biotech. Bioeng. 73 (2001) 261-270. Transient expression is described by, e.g., Durocher, Y., et al., Nucl. Acids. Res. 30
(2002) E9. Cloning of variable domains is described by Orlandi, R., et al., Proc.
Natl. Acad. Sci. USA 86 (1989) 3833-3837; Carter, P., et al., Proc. Natl. Acad. Sci.
USA 89 (1992) 4285-4289; Norderhaug, L., et al., J. Immunol. Methods 204
(1997) 77-87. A preferred transient expression system (HEK 293) is described by Schlaeger, E.-J. and Christensen, K., in Cytotechnology 30 (1999) 71-83, and by
Schlaeger, E.-J., in J. Immunol. Methods 194 (1996) 191-199.
Monoclonal antibodies are suitably separated from the culture medium by conventional immunoglobulin purification procedures such as, for example, protein A-Sepharose, hydroxylapatite chromatography, gel electrophoresis, dialysis, or affinity chromatography. DNA and RNA encoding the monoclonal antibodies is readily isolated and sequenced using conventional procedures. The hybridoma cells can serve as a source of such DNA and RNA. Once isolated, the DNA may be inserted into expression vectors, which are then transfected into host cells, such as HEK 293 cells, CHO cells, or myeloma cells that do not otherwise produce immunoglobulin protein, to obtain the synthesis of recombinant monoclonal antibodies in the host cells.
Amino acid sequence variants of human EPO-R antibody are prepared by introducing appropriate nucleotide changes into the antibody encoding DNA, or by peptide synthesis. Such modifications can be performed, however, only in a very limited range, e.g. as described above. For example, the modifications do not alter the abovementioned antibody characteristics such as the IgG isotype and epitope binding, but may improve the yield of the recombinant production, protein stability, or facilitate the purification.
Any cysteine residue not involved in maintaining the proper conformation of the anti- EPO-R antibody may also be substituted, generally with serine, to improve the oxidative stability of the molecule and to prevent aberrant crosslinking. Conversely, cysteine bond(s) may be added to the antibody to improve its stability (particularly where the antibody is an antibody fragment such as an Fv fragment).
Nucleic acid molecules encoding amino acid sequence variants of anti- EPO-R antibody are prepared by a variety of methods known in the art. These methods include, but are not limited to, isolation from a natural source (in the case of naturally occurring amino acid sequence variants) or preparation by oligonucleotide-mediated (or site-directed) mutagenesis, PCR mutagenesis, and cassette mutagenesis of an earlier prepared variant or a non-variant version of humanized anti- EPO-R antibody.
The heavy and light chain variable domains according to the invention are combined with sequences of promoter, translation initiation, constant region, 3' untranslated region, polyadenylation, and transcription termination to form expression vector constructs. The heavy and light chain expression constructs can be combined into a single vector, co-transfected, serially transfected, or separately transfected into host cells which are then fused to form a single host cell expressing both chains. In another aspect, the present invention provides a diagnostic composition, e.g. for the determination of activated EPO-R in human cells tissues, and biopsies.
Description of the Sequences
SEQ ID NO: 1 heavy chain CDR3, Mab Cl.16.7.5 SEQ ID NO: 2 heavy chain CDR2, Mab Cl.16.7.5
SEQ ID NO: 3 heavy chain CDRl , Mab Cl.16.7.5
SEQ ID NO: 4 light chain CDR3, Mab Cl.16.7.5
SEQ ID NO: 5 light chain CDR2, Mab Cl.16.7.5
SEQ ID NO: 6 light chain CDRl, Mab Cl.16.7.5 SEQ ID NO: 7 heavy chain variable domain, Mab Cl.16.7.5
SEQ ID NO: 8 light chain variable domain , Mab Cl.16.7.5
SEQ ID NO: 9 heavy chain CDR3, Mab Cl.8.7.16
SEQ ID NO: 10 heavy chain CDR2, Mab Cl.8.7.16
SEQ ID NO: 11 heavy chain CDRl, Mab Cl.8.7.16 SEQ ID NO: 12 light chain CDR3, Mab Cl.8.7.16
SEQ ID NO: 13 light chain CDR2, Mab Cl.8.7.16
SEQ ID NO: 14 light chain CDRl, Mab Cl.8.7.16
SEQ ID NO: 15 heavy chain variable domain, Mab Cl.8.7.16
SEQ ID NO: 16 light chain variable domain , Mab Cl.8.7.16 SEQ ID NO: 17 heavy chain CDR3, Mab Cl.24.11.31
SEQ ID NO: 18 heavy chain CDR2, Mab C1.24.11.31
SEQ ID NO: 19 heavy chain CDRl, Mab Cl.24.1 1.31
SEQ ID NO: 20 light chain CDR3, Mab Cl.24.11.31
SEQ ID NO: 21 light chain CDR2, Mab Cl.24.11.31 SEQ ID NO: 22 light chain CDRl , Mab C1.24.11.31
SEQ ID NO: 23 heavy chain variable domain, Mab C1.24.11.31
SEQ ID NO: 24 light chain variable domain , Mab C1.24.11.31
SEQ ID NO: 25 synthetic peptide
SEQ ID NO: 26 synthetic peptide
Description of the Figures i
Figure 1: Time dependent phosphorylation of human EPOR in UT-
7 EPOR cells. Western blot analysis of lysates of UT7-EPOR cells stained with the different monoclonal antibodies directed against phosphorylated human EPOR. (a) pY430 (Cl.16.7.5), (b) pY461 (Cl.8.7.16), (c) pY465 (C1.24.11.31). All monoclonal antibodies specifically detect EPOR only when cells are stimulated with EPO, unstimulated cells (-) are not labeled by the antibodies. GAPDH (Glyceraldehyde 3-phosphate dehydrogenase) was used as loading control.
Example 1
Generation of phospho-specific EPOR monoclonal antibodies
pY430 (Cl.16.7.5): a 17 amino-acid synthetic peptide corresponding to residues
424-437 of the mature human erythropoietin receptor (TPPHLKYLYLVVSD, SEQ ID NO:25), comprising a phospho-tyrosyl residue at position 430 was used as immunogen. pY461 (Cl.8.7.16): a 17 amino-acid synthetic peptide corresponding to residues 455-471 of the mature human erythropoietin receptor (GLSDGPYSNP YENSLIP,
SEQ ID NO:26), comprising a phospho-tyrosyl residue at position 461 was used as immunogen. pY465 (Cl.24.11.31): a 17 amino-acid synthetic peptide corresponding to residues 455-471 of the mature human erythropoietin receptor (GLSDGP YSNPYENSLIP, SEQ ID NO:26), comprising a phospho-tyrosyl residue at position 465 was used as immunogen.
For immunization the peptides were coupled to KLH via a C terminal cystein. Balb/c mice were immunized with immunogen every four weeks for 3 times followed by an i.v. boost on day 4 before fusion, splenocytes were harvested, and fused with Ag8 myeloma cells. Screening for phospho-specific antibodies was done by differential testing on phospho -vs. non-phospho form of the peptide (which otherwise was identical to the phospho-peptide) using peptide coated ELISA microtiter plates following standard procedues. Antibody clones were selected because they detected one specific band corresponding to the EPOR on Western Blots of cell lysates that have been stimulated with EPO (example 2).
SDS-PAGE and Western blotting:
The SDS-PAGE and Western blotting were performed according to standard procedures and the Nupage® gel system of Invitrogen. The lysates corresponding to 5.104-105 cells were loaded in each line of a Nupage® Novex 4-12% Bis-Tris gel. The proteins were then transferred onto PVDF (Polyvinylidene Fluoride) membranes and incubated with the antibodies and anti-GAPDH antibody (Abeam m9484, Abeam pic UK)) for 2 hours at room temperature or overnight at 4°C . After washing, the membranes were incubated with a conjugate anti-mouse IgG- POD and developed using ECL reagents (Lumi-LightPLUS Western blotting substrate, Roche Applied Science #2015218).
Antibodies C1.24.11.31, Cl.16.7.5 and Cl.8.7.16 were selected as binding specifically to activated EPO receptor only without binding to non-activated EPO receptor (Fig.l).
Example 2
Activation of UT-7 cells
UT-7 cell line is a human factor-dependent erythroleukemic cell line (Human bone marrow acute myeloid leukemia cell line DSMZ: ACC 137), requiring EPO for long-term growth. UT7 cells were maintained in RPMI medium comprising in addition L-glutamine (2mM), non-essential amino acids (Ix), and sodium pyruvate
(ImM) (starvation medium), supplemented with 10% fetal calf serum and lOU/ml GM-CSF. Transduced cells (UT7/EPOR) were maintained in the same medium as untransduced (25U/ml GM-CSF instead of 10U/ml) with the addition of 0.4 mg/ml zeocine. Before each stimulation the cells were starved by incubation overnight in RPMI media supplemented with L-glutamine (2mM), non-essential amino acids
(Ix), sodium pyruvate (ImM) and 0.1% fetal calf serum.
Transduction:
UT-7 cells were transduced with the supernatant from GP2-293 (Clontech Laboratories, Inc) cells transiently transfected with a retroviral expression vector encoding hEPOR and pVSV-G (an expression vector encoding the G glycoprotein of the rhabdovirus vesicular stomatitis virus). Two days after transduction the medium was replaced with fresh supplemented RPMI containing 0.4 mg/ml zeocine and 25U/ml GM-CSF. After selection a cell line of UT-7 cells stable expressing EPOR on their surface was obtained. Stimulation:
Serum starved cells were stimulated for the times indicated with 500 pM erythropoietin in starvation medium (supplemented with 0.1% fetal calf serum) at 37°C for 1, 3 and 5 minutes. After stimulation the cells were centrifuged, the medium was discarded and the pellet was incubated in ice-cold lysis buffer [Tris 20 mM (pH7.4), NaCl 137 mM, Glycerol 10%, Nonidet® P-40 1% , protease inhibitors Ix (Pierce, # 78410), phosphatase inhibitors Ix (Pierce #78420)] for 30 minutes at 4°C followed by centrifugation at 13000 rpm for 10 minutes at 4°C. The lysate supernatant was boiled in sample buffer (Nupage®, Invitrogen) in the presence of a reducing agent and either directly used for SDS-PAGE.
Specific binding of the Mabs was tested by ELISA on microtiterplates coated with the corresponding biotinylated peptide according to standard procedures as described in example 1. Already within 1 min a clear activation of human EPOR can be demonstrated while un-stimulated cells do not show any detectable basal level of activation.
Example 3
Western Blot assay for binding of Mabs to UT-7/EPOR cells activated by
EPO
UT7/EPOR cells were stimulated as described above and analyzed by Western Blot. On Western blot the Mabs recognize one band at MW 66kD corresponding to the EPOR (Fig.l) in cells that are stimulated with 0.5nM EPO for 1-5 min. Already within 1 min a clear activation of human EPOR can be demonstrated while unstimulated cells do not show any detectable basal level of activation (Fig.l). As loading control GAPDH was used. Thus, these antibodies specifically analyze the activation of EPOR by ESAs (erythropoietin stimulating agents).

Claims

Patent Claims
1. Antibody binding to human EPO receptor, characterized in specifically binding EPO receptor fragment TPPHLKYLYLVVSD (SEQ ID NO:25) comprising a phospho-tyrosyl residue at position 430, GLSDGPYSNPYENSLIP (SEQ ID NO:26) comprising a phospho-tyrosyl residue at position 461, or GLSDGPYSNPYENSLIP (SEQ ID NO:26) comprising a phospho-tyrosyl residue at position 465.
2. Antibody according to claim 1, characterized in comprising as heavy chain variable domain CDR3 region a CDR3 region of SEQ ID NO: I5 9 or 17.
3. Antibody according to claim 1, characterized in that the heavy chain variable domain comprises CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO:2 and a CDRl region of SEQ ID NO:3 or a CDR3 region of SEQ ID NO:9, a CDR2 region of SEQ ID NO: 10 and a CDRl region of SEQ ID NO: 11 or a CDR3 region of SEQ ID NO: 17, a CDR2 region of SEQ ID NO: 18 and a CDRl region of SEQ ID NO: 19.
4. Antibody according to claim 1 or 2, characterized in that the heavy chain variable domain comprises SEQ ID NO:7 and the light chain variable domain comprises SEQ ID NO: 8 or that the heavy chain variable domain comprises SEQ ID NO: 15 and the light chain variable domain comprises SEQ ID NO: 16 or that the heavy chain variable domain comprises SEQ ID NO:23 and the light chain variable domain comprises SEQ ID NO:24.
5. Nucleic acid encoding a heavy chain of an antibody according to claim 3, said heavy chain being characterized in comprising a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO:2 and a CDRl region of SEQ ID NO:3 or a CDR3 region of SEQ ID NO:9, a CDR2 region of SEQ ID NO: 10 and a CDRl region of SEQ ID NO: 11 or a CDR3 region of SEQ ID NO: 17, a CDR2 region of SEQ ID NO: 18 and a CDRl region of SEQ ID NO: 19.
6. Nucleic acid encoding a heavy chain of an antibody according to claim4, said heavy chain being characterized in comprising as variable domain SEQ ID NO:7, SEQ ID NO: 15 or SEQ ID NO: 19.
7. Method for the manufacture of a diagnostic kit comprising an antibody according to claims 1 to 4.
8. Expression vector characterized in comprising a nucleic acid according to claims 5 or 6.
9. Prokaryotic or eukaryotic host cell characterized in comprising a vector according to claim 8.
10. Method for the production of a recombinant human or humanized antibody according claims 3 or 4, characterized by expressing a nucleic acid according claims 5 or 6 in a prokaryotic or eukaryotic host cell and recovering said antibody from said cell or the cell culture supernatant.
1 1. Use of an antibody according to claims 1 to 4 for the determination of activated EPO receptor in human cells tissues, and biopsies .
12. Use according to claim 11, characterized in that the sample is a lysate of human tissue.
13. Use according to claim 12, characterized in that the determination is performed by Western Blot or ELISA
14. Antibody according to claims 1 to 4 for use in the determination of activated
EPO receptor in human cells tissues, and biopsies.
PCT/EP2010/000130 2009-01-15 2010-01-13 Antibodies against human epo receptor WO2010081679A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2011545672A JP2012514985A (en) 2009-01-15 2010-01-13 Antibody against human EPO receptor
US13/144,671 US9221909B2 (en) 2009-01-15 2010-01-13 Antibodies against human EPO receptor
CN201080004518.2A CN102282174B (en) 2009-01-15 2010-01-13 Antibodies against human epo receptor
ES10700705.6T ES2528219T3 (en) 2009-01-15 2010-01-13 Antibodies against the human EPO receptor
SG2011050168A SG172927A1 (en) 2009-01-15 2010-01-13 Antibodies against human epo receptor
EP10700705.6A EP2387586B1 (en) 2009-01-15 2010-01-13 Antibodies against human epo receptor
CA2748758A CA2748758C (en) 2009-01-15 2010-01-13 Antibodies against phosphorylated tyrosines on erythropoietin receptor (epor)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09000499.5 2009-01-15
EP09000499 2009-01-15

Publications (2)

Publication Number Publication Date
WO2010081679A2 true WO2010081679A2 (en) 2010-07-22
WO2010081679A3 WO2010081679A3 (en) 2010-09-23

Family

ID=40379757

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2010/000130 WO2010081679A2 (en) 2009-01-15 2010-01-13 Antibodies against human epo receptor

Country Status (8)

Country Link
US (1) US9221909B2 (en)
EP (1) EP2387586B1 (en)
JP (4) JP2012514985A (en)
CN (1) CN102282174B (en)
CA (3) CA2748758C (en)
ES (1) ES2528219T3 (en)
SG (1) SG172927A1 (en)
WO (1) WO2010081679A2 (en)

Cited By (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8623666B2 (en) 2011-06-15 2014-01-07 Hoffmann-La Roche Inc. Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9212181B2 (en) 2008-06-27 2015-12-15 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US9365646B2 (en) 2012-12-05 2016-06-14 Novartis Ag Compositions and methods for antibodies targeting EPO
US9409921B2 (en) 2008-06-27 2016-08-09 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines as kinase inhibitors
US9409887B2 (en) 2010-11-10 2016-08-09 Celgene Avilomics Research, Inc. Mutant-selective EGFR inhibitors and uses thereof
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9604936B2 (en) 2010-08-10 2017-03-28 Celgene Car Llc Besylate salt of a BTK inhibitor
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US11725246B2 (en) 2015-08-12 2023-08-15 Novartis Ag Methods of treating ophthalmic disorders

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2321350A1 (en) * 2008-08-28 2011-05-18 F. Hoffmann-La Roche AG Antibodies against human epo receptor
WO2010081679A2 (en) * 2009-01-15 2010-07-22 F. Hoffmann-La Roche Ag Antibodies against human epo receptor
JP7320291B2 (en) 2021-07-12 2023-08-03 有限会社 エコ・ライス新潟 Liquid freezer storage container and long-term storage method for beverage

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005469A1 (en) 1993-08-16 1995-02-23 Lee Jong Y Human erythropoietin receptor fragment and antibodies thereto
WO1996003438A1 (en) 1994-07-26 1996-02-08 Amgen Inc. Antibodies which activate an erythropoietin receptor
WO2000061637A1 (en) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
EP1327681A1 (en) 2000-10-20 2003-07-16 Chugai Seiyaku Kabushiki Kaisha Degraded agonist antibody
US20040058393A1 (en) 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
US20040071694A1 (en) 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
WO2004035603A2 (en) 2002-10-14 2004-04-29 Abbott Laboratories Erythropoietin receptor binding antibodies
US20040175379A1 (en) 2002-10-14 2004-09-09 Devries Peter J. Erythropoietin receptor binding antibodies
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US20060018902A1 (en) 2004-04-09 2006-01-26 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
US6998124B1 (en) 1999-04-14 2006-02-14 Smithkline Beecham Corporation Erythropoietin receptor antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1654377A4 (en) 2002-03-01 2010-03-24 Roger Williams Hospital Shc PROTEIN-RELATED METHODS AND COMPOSITIONS FOR THE PROGNOSIS OF BREAST, PROSTATE AND OVARIAN CANCER
JP2003310276A (en) * 2002-04-30 2003-11-05 Kyowa Hakko Kogyo Co Ltd SUBSTANCE BLOCKING SIGNAL TRANSDUCTION MOLECULE TO KDR/ Flk-1 HAVING PHOSPHORYLATED TYROSINE AT 1214 POSITION
JP2005089354A (en) * 2003-09-16 2005-04-07 Kyowa Hakko Kogyo Co Ltd Antibody selectively recognizing phosphorylated beta-catenin
CN1686543A (en) * 2005-05-09 2005-10-26 叶新新 MODS-MOF interversion treating medicine EPO antibody EPO receptor, manufacturing method and animal model
US20080124340A1 (en) * 2006-04-14 2008-05-29 Borges Luis G Erythropoietin receptor agonists
WO2010081679A2 (en) * 2009-01-15 2010-07-22 F. Hoffmann-La Roche Ag Antibodies against human epo receptor

Patent Citations (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995005469A1 (en) 1993-08-16 1995-02-23 Lee Jong Y Human erythropoietin receptor fragment and antibodies thereto
EP0776370A1 (en) 1993-08-16 1997-06-04 Jong Y. Lee Human erythropoietin receptor fragment and antibodies thereto
US20020031806A1 (en) 1993-08-16 2002-03-14 Jong Y. Lee Purified human erythropoietin receptor protein fragment and antibodies derived therefrom
US7053184B2 (en) 1993-08-16 2006-05-30 Lee Jong Y Purified human erythropoietin receptor protein fragment and antibodies derived therefrom
WO1996003438A1 (en) 1994-07-26 1996-02-08 Amgen Inc. Antibodies which activate an erythropoietin receptor
EP0773962A1 (en) 1994-07-26 1997-05-21 Amgen Inc. Antibodies which activate an erythropoietin receptor
US7081523B2 (en) 1994-07-26 2006-07-25 Amgen Inc. Antibodies which activate an erythropoietin receptor
EP1146056A1 (en) 1994-07-26 2001-10-17 Amgen, Inc. Antibodies which activate an erythropoietin receptor
US20030215444A1 (en) 1994-07-26 2003-11-20 Amgen Inc. Antibodies which activate an erythropoietin receptor
US20050244409A1 (en) 1999-04-14 2005-11-03 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US6998124B1 (en) 1999-04-14 2006-02-14 Smithkline Beecham Corporation Erythropoietin receptor antibodies
WO2000061637A1 (en) 1999-04-14 2000-10-19 Smithkline Beecham Corporation Erythropoietin receptor antibodies
US20040058393A1 (en) 2000-04-17 2004-03-25 Naoshi Fukishima Agonist antibodies
EP1327681A1 (en) 2000-10-20 2003-07-16 Chugai Seiyaku Kabushiki Kaisha Degraded agonist antibody
US20040071694A1 (en) 2002-10-14 2004-04-15 Devries Peter J. Erythropoietin receptor binding antibodies
WO2004035603A2 (en) 2002-10-14 2004-04-29 Abbott Laboratories Erythropoietin receptor binding antibodies
US20040175379A1 (en) 2002-10-14 2004-09-09 Devries Peter J. Erythropoietin receptor binding antibodies
US20050227289A1 (en) 2004-04-09 2005-10-13 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof
WO2005100403A2 (en) 2004-04-09 2005-10-27 Abbott Laboratories Antibodies to erythropoietin receptor and uses thereof
US20060018902A1 (en) 2004-04-09 2006-01-26 Reilly Edward B Antibodies to erythropoietin receptor and uses thereof

Non-Patent Citations (36)

* Cited by examiner, † Cited by third party
Title
"Current Protocols in Molecular Biology", 1987, GREENE PUBLISHING AND WILEY INTERSCIENCE
ANDREA, A.D., BLOOD, vol. 82, 1993, pages 46 - 52
ARAI, A. ET AL., J. BIOL. CHEM., vol. 276, 2001, pages 33282 - 33290
BARBER, D. L. ET AL., BLOOD, vol. 97, 2001, pages 2230 - 2237
BARNES, L.M. ET AL., BIOTECH. BIOENG., vol. 73, 2001, pages 261 - 270
BARNES, L.M. ET AL., CYTOTECHNOLOGY, vol. 32, 2000, pages 109 - 123
BERGELSON, S. ET AL., J. BIOL. CHEM., vol. 273, 1998, pages 2396 - 2401
CARTER, P. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 4285 - 4289
DAMEN, J. E. ET AL., J. BIOL. CHEM, vol. 270, 1995, pages 23402 - 23408
DUROCHER, Y. ET AL., NUCL. ACIDS. RES., vol. 30, 2002, pages E9
ELLIOTT, S., BLOOD, vol. 107, 2006, pages 1892 - 1895
GEISSE, S. ET AL., PROTEIN EXPR. PURIF., vol. 8, 1996, pages 271 - 282
HOUSTON, J.S., METHODS ENZYMOL., vol. 203, 1991, pages 46 - 88
JELKMANN, W. ET AL., CRIT. REV. ONC/HEMATOL., vol. 67, 2008, pages 39 - 61
JOHNSON, G.; WU, T.T., NUCLEIC ACIDS RES., vol. 28, 2000, pages 214 - 218
JONES, S.S. ET AL., BLOOD, vol. 76, 1990, pages 31 - 35
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NATIONAL INSTITUTES OF HEALTH
KAUFMAN, R.J., MOL. BIOTECHNOL., vol. 16, 2000, pages 151 - 161
KIRKEBY, A., J. NEROSCI., vol. 164, 2007, pages 50 - 58
LI, K. ET AL., J. BIOL. CHEM., vol. 278, 2003, pages 40702 - 40709
MAKRIDES, S.C., PROTEIN EXPR. PURIF., vol. 17, 1999, pages 183 - 202
MATTHEWS, D.J., PNAS, vol. 93, 1996, pages 9471 - 9476
MILLER, B. A. ET AL., J. BIOL. CHEM., vol. 274, 1999, pages 20465 - 20472
MIURA, 0., ARCH. BIOCHEM., vol. 306, 1993, pages 200 - 208
NEUBERGER, M.S. ET AL., NATURE, vol. 314, 1985, pages 268 - 270
NORDERHAUG, L. ET AL., J. IMMUNOL. METHODS, vol. 204, 1997, pages 77 - 87
ORLANDI, R. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 3833 - 3837
QUEEN, C. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 10029 - 10033
RIECHMANN, L. ET AL., NATURE, vol. 332, 1988, pages 323 - 327
SCHLAEGER, E.-J., J. IMMUNOL. METHODS, vol. 194, 1996, pages 191 - 199
SCHLAEGER, E.-J.; CHRISTENSEN, K., CYTOTECHNOLOGY, vol. 30, 1999, pages 71 - 83
SYTKOWSKI, A.J.: "Erythropoietin", 2004, WILEY-VCH VERLAG GMBH & CO., pages: 73 - 100
WERNER, R.G., DRUG RES., vol. 48, 1998, pages 870 - 880
WINKELMANN, J.C. ET AL., BLOOD, vol. 76, 1990, pages 24 - 30
WU, H. ET AL., PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 1806 - 1810
WU, H. ET AL.: "report the functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation", PROC. NATL. ACAD. SCI. USA, vol. 94, 1997, pages 1806 - 1810, XP002526125, DOI: doi:10.1073/pnas.94.5.1806

Cited By (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9296737B2 (en) 2008-06-27 2016-03-29 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US10828300B2 (en) 2008-06-27 2020-11-10 Celgene Car Llc Substituted 2,4-diaminopyrimidines as kinase inhibitors
US10596172B2 (en) 2008-06-27 2020-03-24 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US10010548B2 (en) 2008-06-27 2018-07-03 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US9987276B2 (en) 2008-06-27 2018-06-05 Celgene Car Llc Substituted 2,4-diaminopyrimidines as kinase inhibitors
US9212181B2 (en) 2008-06-27 2015-12-15 Celgene Avilomics Research, Inc. Substituted 2,4-diaminopyrimidines as kinase inhibitors
US9409921B2 (en) 2008-06-27 2016-08-09 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines as kinase inhibitors
US9604936B2 (en) 2010-08-10 2017-03-28 Celgene Car Llc Besylate salt of a BTK inhibitor
US10081606B2 (en) 2010-11-01 2018-09-25 Celgene Car Llc Heteroaryl compounds and uses thereof
US8975249B2 (en) 2010-11-01 2015-03-10 Celgene Avilomics Research, Inc. Heterocyclic compounds and uses thereof
US9375431B2 (en) 2010-11-01 2016-06-28 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidine compounds useful as kinase inhibtors
US9238629B2 (en) 2010-11-01 2016-01-19 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US11096942B2 (en) 2010-11-01 2021-08-24 Celgene Car Llc Heterocyclic compounds and uses thereof
US10434101B2 (en) 2010-11-01 2019-10-08 Celgene Car Llc Heterocyclic compounds and uses thereof
US9867824B2 (en) 2010-11-01 2018-01-16 Celgene Car Llc Heterocyclic compounds and uses thereof
US9765038B2 (en) 2010-11-01 2017-09-19 Celgene Car Llc Heteroaryl compounds and uses thereof
US9409887B2 (en) 2010-11-10 2016-08-09 Celgene Avilomics Research, Inc. Mutant-selective EGFR inhibitors and uses thereof
US9868723B2 (en) 2010-11-10 2018-01-16 Celgene Car Llc Mutant-selective EGFR inhibitors and uses thereof
US9187563B2 (en) 2011-06-15 2015-11-17 Hoffmann-La Roche Inc. Anti-human EPO receptor antibodies and methods of use
US8623666B2 (en) 2011-06-15 2014-01-07 Hoffmann-La Roche Inc. Method for detecting erythropoietin (EPO) receptor using anti-human EPO receptor antibodies
US9364476B2 (en) 2011-10-28 2016-06-14 Celgene Avilomics Research, Inc. Methods of treating a Bruton's Tyrosine Kinase disease or disorder
US9539255B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US10005738B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US10570099B2 (en) 2012-03-15 2020-02-25 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US9108927B2 (en) 2012-03-15 2015-08-18 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US9540335B2 (en) 2012-03-15 2017-01-10 Celgene Avilomics Research, Inc. Salts of an epidermal growth factor receptor kinase inhibitor
US11292772B2 (en) 2012-03-15 2022-04-05 Celgene Car Llc Salts of an epidermal growth factor receptor kinase inhibitor
US10946016B2 (en) 2012-03-15 2021-03-16 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US9056839B2 (en) 2012-03-15 2015-06-16 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
US10004741B2 (en) 2012-03-15 2018-06-26 Celgene Car Llc Solid forms of an epidermal growth factor receptor kinase inhibitor
US10385127B2 (en) 2012-12-05 2019-08-20 Novartis Ag Compositions and methods for antibodies targeting EPO
US10106605B2 (en) 2012-12-05 2018-10-23 Novartis Ag Compositions and methods for antibodies targeting Epo
US9365646B2 (en) 2012-12-05 2016-06-14 Novartis Ag Compositions and methods for antibodies targeting EPO
US9126950B2 (en) 2012-12-21 2015-09-08 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9549927B2 (en) 2012-12-21 2017-01-24 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9504686B2 (en) 2013-02-08 2016-11-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9561228B2 (en) 2013-02-08 2017-02-07 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
US9980964B2 (en) 2013-02-08 2018-05-29 Celgene Car Llc ERK inhibitors and uses thereof
US9796700B2 (en) 2013-02-08 2017-10-24 Celgene Car Llc ERK inhibitors and uses thereof
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
US10202364B2 (en) 2014-08-13 2019-02-12 Celgene Car Llc Forms and compositions of an ERK inhibitor
US10005760B2 (en) 2014-08-13 2018-06-26 Celgene Car Llc Forms and compositions of an ERK inhibitor
US11725246B2 (en) 2015-08-12 2023-08-15 Novartis Ag Methods of treating ophthalmic disorders

Also Published As

Publication number Publication date
CA2965031C (en) 2018-12-04
CN102282174B (en) 2014-02-26
SG172927A1 (en) 2011-08-29
CA3018087A1 (en) 2010-07-22
US20120122120A1 (en) 2012-05-17
EP2387586A2 (en) 2011-11-23
CA2748758A1 (en) 2010-07-22
JP6143921B2 (en) 2017-06-07
JP2016190862A (en) 2016-11-10
CN102282174A (en) 2011-12-14
CA2965031A1 (en) 2010-07-22
CA2748758C (en) 2017-06-13
JP6363255B2 (en) 2018-07-25
US9221909B2 (en) 2015-12-29
WO2010081679A3 (en) 2010-09-23
CA3018087C (en) 2019-09-24
JP2014204721A (en) 2014-10-30
EP2387586B1 (en) 2014-12-17
JP2012514985A (en) 2012-07-05
ES2528219T3 (en) 2015-02-05
JP2017136093A (en) 2017-08-10
JP5980265B2 (en) 2016-08-31

Similar Documents

Publication Publication Date Title
JP6363255B2 (en) Antibody against human EPO receptor
US11976136B2 (en) IgG bispecific antibodies and processes for preparation
JP5522405B2 (en) Stable multivalent antibody
DK2146745T3 (en) Penta-specific antibody
KR20130062369A (en) Antibodies against human tweak and uses thereof
WO2021139758A1 (en) New polypeptide complex
JP2022517720A (en) Methods for characterizing disulfide bonds
CN114634566B (en) Antigen binding fragment of Claudin18_2, antibody and application thereof
CN115109154A (en) Antibody targeting CLDN18.2 or antigen binding fragment thereof and application thereof
US20240141071A1 (en) Antibodies that bind cd123 and gamma-delta t cell receptors
CN111892657B (en) Antibody, fragment, kit and method for detecting Mi Tianbao blood group antigen
US11155635B2 (en) Anti-coagulation factor VIII antibody and use thereof
JP2012528812A (en) Antibodies against human CCN1 and uses thereof
EP2321350A1 (en) Antibodies against human epo receptor
CN115850458A (en) Anti-coronavirus RBD protein antibody, preparation method and application
WO2023125793A1 (en) Anti-ccr6 antibodies and uses thereof
WO2024047079A1 (en) Anti-cb2 antibodies and their use in a flow cytometry assay to measure cell surface cb2 expression
IL305346A (en) Antibodies that bind cd123 and gamma-delta t cell receptors
ZA200602015B (en) Antibodies against interleukin-1receptor and uses thereof

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080004518.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10700705

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2748758

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010700705

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2011545672

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 13144671

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 1538/MUMNP/2011

Country of ref document: IN